ArticleWorld journal of urology2024

Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer.

Mike Wenzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.